VolitionRx (NYSE:VNRX) Now Covered by Analysts at Jones Trading

Jones Trading initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $3.00 price objective on the stock.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen initiated coverage on shares of VolitionRx in a research note on Thursday, May 15th. They set a “sell” rating for the company. HC Wainwright initiated coverage on shares of VolitionRx in a research note on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price for the company. Finally, D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.50.

VolitionRx Stock Performance

Shares of VNRX opened at $0.56 on Tuesday. VolitionRx has a fifty-two week low of $0.40 and a fifty-two week high of $0.90. The company has a market capitalization of $57.78 million, a price-to-earnings ratio of -1.56 and a beta of 1.07. The firm has a 50-day simple moving average of $0.50 and a 200-day simple moving average of $0.57.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds acquired 181,818 shares of VolitionRx stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought a total of 271,818 shares of company stock worth $141,100 over the last 90 days. Company insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A number of hedge funds have recently added to or reduced their stakes in VNRX. Lagoda Investment Management L.P. lifted its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Millennium Management LLC acquired a new stake in shares of VolitionRx during the 4th quarter valued at approximately $36,000. Two Sigma Securities LLC acquired a new stake in shares of VolitionRx during the 4th quarter valued at approximately $29,000. Finally, Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.